Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03809663 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
NCT03809663 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 251 participants.
The verdict
NCT03809663, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
Study Summary
This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).
Interventions
- OTHER Placebo
- DRUG Tezepelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2020-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03809663
The ClinicalTrials.gov registry entry for NCT03809663 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03809663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03809663 about?
NCT03809663 is a clinical study titled "A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis". This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).
What is the current status of trial NCT03809663?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2019-03-15. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT03809663?
The interventions under investigation include: Placebo (OTHER), Tezepelumab (DRUG).
Who is sponsoring clinical trial NCT03809663?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.